Utility of QuantiFERON-TB Gold in-tube testing for latent TB infection in HIV-infected individuals

International Journal of Tuberculosis and Lung Disease

Volumn 11, Issue 11, 2007, Pages 1190-1195

  Jones, Sian ^a   De Gijsel, D ^b   Wallach, F R ^b   Gurtman, A C ^c   Shi, Q ^d   Sacks, H ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Vaccine Research   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

ELISA; HIV; Interferon; QuantiFERON; Tuberculosis

Indexed keywords

ANTIGEN; CULTURE FILTRATE PROTEIN 10 ANTIGEN; EARLY SECRETORY ANTIGENIC TARGET 6; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY APPARATUS, EQUIPMENT AND SUPPLIES; LATENT PERIOD; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TUBERCULIN TEST;

ADULT; AGED; CD4 LYMPHOCYTE COUNT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HUMANS; INTERFERON TYPE II; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS;

EID: 36348988505     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Selwyn P A, Hartel D, Lewis V A, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320: 545-550.
2. Markowitz N, Hansen N I, Wilcosky T C, et al. Tuberculin and anergy testing in HIV seropositive and HIV seronegative persons. Pulmonary complications of HIV infection study group. Ann Intern Med 1993; 119: 185-193.
3. Anastos K, Kalish L A, Palacio H, et al. Prevalence of and risk factors for tuberculin positivity and skin test anergy in HIV-1 infected and uninfected at-risk women. Women's Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr 1999; 21: 141-147.
4. Mazurek G H, Jereb J, Lobue P, Iademarco M F, Metchock B, Vernon A. Division of Tuberculosis Elimination, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention (CDC). Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005; 54: 49-55.
5. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon-gamma based assay using new antigens. Am J Respir Crit Care Med 2004; 17: 59-64.
6. Brock I, Weldingh K, Lillebaek T, Follmann F, Anderson P. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004; 170: 65-69.
7. Lalvani A, Pathan A A, McShane H, et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen specific T cells. Am J Respir Crit Care Med 2001; 163: 824-828.
8. Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen L R, Ravn P. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon gamma test. Respir Res 2006; 7: 56.
9. Luetkemeyer A F, Charlebois E D, Flores L L, et al. Comparison of an interferon gamma release assay to tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med 2007; 175: 737-742.
10. Mazurek G H, LoBue P A, Daley C L, et al. Comparison of a whole blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001; 286: 1740-1747.
11. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Recomm Rep 1998; 47: 1-58.
12. Chaisson R E, Keruly J C, McAvinue S, Gallant J E, Moore R D. Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11: 455-459.
13. Bearman J E. A study of variability in tuberculin test reading. Am Rev Respir Dis 1964; 90: 913-919.
14. Ferrrara G, Losi M, Meacci M, et al. Routine hospital use of a commercial whole blood interferon-gamma assay for tuberculosis infection. Am J Respir Crit Care Med 2005; 172: 631-635.
15. Dheda K, Lalvani A, Miller R F, et al. Performance of a T-cell based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS 2005; 19: 2038-2041.
16. Arend S M, Thijsen S F T, Leyten E M S, et al. Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts. Am J Respir Crit Care Med 2007; 175: 618-627.
17. Carrara S, Vincenti D, Petrosillo N, Amicosante M, Girardi E, Goletti D. Use of a T-cell based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis 2004; 38: 754-756.
18. Wu-Hsieh B A, Chen C K, Chang J H, et al. Long-lived immune response to early secretory antigenic target 6 in individuals who had recovered from tuberculosis. Clin Infect Dis 2001; 33: 1336-1340.
19. Kang Y A, Lee H W, Yoon H I, et al. Discrepancy between the tuberculin skin test and the whole blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis burden country. JAMA 2005; 293: 2756-2761.
20. Kimura M, Converse P J, Astemborski J, et al. Comparison between a whole blood interferon-gamma release assay and tuberculin skin testing for the detection of tuberculosis infection among patients at risk for tuberculosis exposure. J Infect Dis 1999; 179: 1297-1300.
21. Dewan P K, Grinsdale J, Liska S, Wong E, Fallstad R, Kawamura L M. Feasibility, acceptability and cost of tuberculosis testing by whole-blood interferon-gamma assay. BMC Infect Dis 2006; 6: 47.